ATE224736T1 - Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie - Google Patents

Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie

Info

Publication number
ATE224736T1
ATE224736T1 AT98928391T AT98928391T ATE224736T1 AT E224736 T1 ATE224736 T1 AT E224736T1 AT 98928391 T AT98928391 T AT 98928391T AT 98928391 T AT98928391 T AT 98928391T AT E224736 T1 ATE224736 T1 AT E224736T1
Authority
AT
Austria
Prior art keywords
disorganizes
nucleic acid
extracellular matrix
gene therapy
substance
Prior art date
Application number
AT98928391T
Other languages
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Ass Fr Contre Les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Ass Fr Contre Les Myopathies filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE224736T1 publication Critical patent/ATE224736T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98928391T 1997-05-29 1998-05-29 Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie ATE224736T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9706600A FR2763958A1 (fr) 1997-05-29 1997-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
PCT/FR1998/001084 WO1998053853A1 (fr) 1997-05-29 1998-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique

Publications (1)

Publication Number Publication Date
ATE224736T1 true ATE224736T1 (de) 2002-10-15

Family

ID=9507375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98928391T ATE224736T1 (de) 1997-05-29 1998-05-29 Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie

Country Status (12)

Country Link
US (1) US6258791B1 (de)
EP (1) EP0980263B1 (de)
JP (1) JP2002500662A (de)
AT (1) ATE224736T1 (de)
AU (1) AU752146B2 (de)
CA (1) CA2291590A1 (de)
DE (1) DE69808274T2 (de)
DK (1) DK0980263T3 (de)
ES (1) ES2181234T3 (de)
FR (1) FR2763958A1 (de)
PT (1) PT980263E (de)
WO (1) WO1998053853A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998945A1 (de) * 1998-09-30 2000-05-10 Transgene S.A. Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
AU2038900A (en) * 1998-12-04 2000-06-26 Genzyme Corporation Methods for increasing the efficiency of gene transfer
DE59906392D1 (de) * 1998-12-23 2003-08-28 Esparma Gmbh Hyaluronatlyase als penetrationsförderer in topischen mitteln
IL152420A0 (en) * 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
US20050004055A1 (en) * 2001-11-26 2005-01-06 Elena Fattori Increasing electro-gene transfer of nucleic acid molecules into host tissue
EP1480656A4 (de) * 2002-02-15 2007-07-18 Res Dev Foundation Hyaluronsäure-vermittelte adenovirus-transduktion
DE10211457A1 (de) * 2002-03-12 2003-09-25 Knoell Hans Forschung Ev Verwendung von Hyaluronatlyase zur Behandlung von Myokardinfarkten
AU2003220115A1 (en) * 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2004098534A2 (en) * 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
EP2330213A1 (de) 2003-03-05 2011-06-08 Halozyme, Inc. Lösliches Hyaluronidaseglykoprotein (sHASEGP), Verfahren zu dessen Herstellung, Verwendungen und pharmazeutische Zusammensetzunge, die dieses umfassen
US20050014714A1 (en) * 2003-06-04 2005-01-20 The Johns Hopkins University Gene delivery to organs
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
US7888201B2 (en) * 2003-11-04 2011-02-15 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor-on-insulator SRAM configured using partially-depleted and fully-depleted transistors
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP2007175021A (ja) * 2005-12-28 2007-07-12 Sysmex Corp 大腸がんのリンパ節転移マーカー
ES2441961T3 (es) * 2007-02-15 2014-02-07 Allergan, Inc. Composiciones de toxina botulínica y métodos
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
EP3612556B8 (de) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Verbesserte lamp konstrukte
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
EP3833398A4 (de) 2018-09-21 2021-12-22 University of Connecticut Zusammensetzungen und verfahren zur wiederherstellung der paternalen ube3a-genexpression bei angelman-syndrom beim menschen
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
US12564646B2 (en) * 2021-06-16 2026-03-03 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012329A2 (en) * 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
HRP930935A2 (en) * 1992-06-11 1994-12-31 Astra Ab New dna sequences
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer

Also Published As

Publication number Publication date
FR2763958A1 (fr) 1998-12-04
US6258791B1 (en) 2001-07-10
DE69808274D1 (de) 2002-10-31
JP2002500662A (ja) 2002-01-08
AU8023898A (en) 1998-12-30
AU752146B2 (en) 2002-09-05
DK0980263T3 (da) 2003-02-03
CA2291590A1 (fr) 1998-12-03
PT980263E (pt) 2003-02-28
EP0980263A1 (de) 2000-02-23
WO1998053853A1 (fr) 1998-12-03
EP0980263B1 (de) 2002-09-25
ES2181234T3 (es) 2003-02-16
DE69808274T2 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
DE69808274D1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
ATE367448T1 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
ZA200405388B (en) Binding proteins as biosensors
DE69637256D1 (de) Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle
ZA200405390B (en) Entrapped binding proteins as biosensors
EP1135532A4 (de) Fluoreszierende proteine aus nicht-biolumineszenten arten der klasse anthozoa, gene die diese proteine kodieren und deren verwendungen
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
UA74325C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ р38, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇХ МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ ЗА ЇХ ДОПОМОГОЮ
BR0210593A (pt) polinucleotìdeos de defensina e métodos de uso
AU2001268468A1 (en) Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE69828045D1 (de) Verbindungen, ihre herstellung und ihre verwendung für den transfer von nucleinsäuren in zellen
DE60235005D1 (de) Nachweis der instabilität von mikrosatelliten und
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
WO2001096373A3 (en) Fluorescent timer proteins and methods for their use
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
FI972170A0 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
CA2273855A1 (en) Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
ATE263239T1 (de) Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
ATE203271T1 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
HUP0101393A1 (hu) Redukáló körülményekre érzékeny transzfektáló kompozíciók, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE275207T1 (de) Dna zur abschätzung des progressionspotentials von zervixläsionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0980263

Country of ref document: EP

REN Ceased due to non-payment of the annual fee